-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Sd+OVLgvbzkxN8wM56pAbDQpuRySS8D+6NHnTQ5JtJ3oX/eeCRVnL8ZWCpVOrxAT vQtsM4PV/b809lAxt3zkSw== 0000950137-96-000814.txt : 19960717 0000950137-96-000814.hdr.sgml : 19960717 ACCESSION NUMBER: 0000950137-96-000814 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 19960528 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACCUMED INTERNATIONAL INC CENTRAL INDEX KEY: 0000888335 STANDARD INDUSTRIAL CLASSIFICATION: 2835 IRS NUMBER: 364054899 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: POS AM SEC ACT: 1933 Act SEC FILE NUMBER: 033-68932 FILM NUMBER: 96572890 BUSINESS ADDRESS: STREET 1: 920 N FRANKLIN ST STREET 2: STE 402 CITY: CHICAGO STATE: IL ZIP: 60610 BUSINESS PHONE: 3126429200 MAIL ADDRESS: STREET 1: 920 N FRANKLIN STREET STREET 2: SUITE 402 CITY: CHICAGO STATE: IL ZIP: 60610 FORMER COMPANY: FORMER CONFORMED NAME: ALAMAR BIOSCIENCES INC DATE OF NAME CHANGE: 19950504 S-3/A 1 FORM S-3/A 1 As filed with the Securities and Exchange Commission on May 28, 1996 Registration No. 33-68932 ================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------------------- POST-EFFECTIVE AMENDMENT NO. 2 ON FORM S-3 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ---------------------- ACCUMED INTERNATIONAL, INC. ------------------------------------------------------ (Exact name of registrant as specified in its charter) ---------------------- DELAWARE 36-405489 - - - ----------------------------------- --------------------- (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 920 N. Franklin, Suite 402 Chicago, Illinois 60610 (312) 642-9200 ------------------------------------------------------------------------ (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) ---------------------- PETER P. GOMBRICH Chief Executive Officer AccuMed International, Inc. 920 N. Franklin, Suite 402 Chicago, Illinois 60610 (312) 642-9200 ------------------------------------------------------------------------ (Name, address, including zip code, and telephone number, including area code, of agent for service) ---------------------- Copy to: GILLES S. ATTIA, ESQ. Graham & James LLP 400 Capitol Mall Suite 2400 Sacramento, California 95814 (916) 558-6700 Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Post-effective Amendment No. 2 to the Registration Statement. If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. [ ] If any of the securities being registered on this Form are to be offered on a delayed on continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. [x] If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ] THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THE REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE. 2 PROSPECTUS 2,069,028 Shares 574,905 Warrants ACCUMED INTERNATIONAL, INC. Common Stock and Redeemable Warrants to Purchase Common Stock This Prospectus relates to (i) 1,725,405 shares of Common Stock, par value $0.01 per share (the "Common Stock"), of AccuMed International, Inc. (the "Company" or "AccuMed International") issuable upon exercise of 1,725,405 redeemable warrants to purchase Common Stock issued by the Company in July, August and September 1993 (the "1993 Warrants"). If all 1993 Warrants are exercised to acquire Common Stock, the Company will receive gross proceeds of $8,627,025. See "Use of Proceeds." This Prospectus also relates to 343,623 shares of Common Stock and 574,905 redeemable warrants to purchase shares of Common Stock (the "Warrants"). These shares of Common Stock and Warrants may be offered and sold from time to time by certain security holders (the "Selling Securityholders") of the Company through ordinary brokerage transactions in the over-the-counter market, in negotiated transactions or otherwise, at market prices prevailing at the time of the sale or at negotiated prices. Each Warrant entitled the registered holder thereof to purchase one share of Common Stock at a price of $5.00, subject to adjustment in certain circumstances, until October 14, 1997. The Warrants are redeemable by the Company at any time commencing October 14, 1993, subject to certain conditions, as are fully described herein. The Company will not receive any of the proceeds from the sale of Common Stock and Warrants offered hereby. See "Risk Factors," "Selling Securityholders" and "Plan of Distribution." The closing prices for the Common Stock and the Warrants, respectively, on May 17, 199, as reported on the National Association of Securities Dealers Automated Quotation System ("Nasdaq"), were $7.13 and $2.31. THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN AFFORD THE LOSS OF THEIR ENTIRE INVESTMENT. SEE "RISK FACTORS". __________________ THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. __________________ No underwriting commissions or discounts will be paid by the Company in connection with this Offering. Estimated expenses payable by the Company in connection with this Offering are approximately $60,000. __________________ This date of this Prospectus is __________, 1996. 3 AVAILABLE INFORMATION The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith files reports, proxy statements and other information with the Commission. Such reports, proxy statements and other information filed by the Company may be inspected and copied at the public reference facilities maintained by the Commission at 450 Fifth Street, N.W., Room 1024, Washington, D.C. 20549, and at the following regional offices: New York Regional Office, 7 World Trade Center, Room 1400, New York, New York 10048 and Chicago Regional Office, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of such material may also be obtained from the Public Reference Section of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. The Common Stock is quoted on the Nasdaq SmallCap Market and reports and other information regarding the Company may be inspected at the National Association of Securities Dealers, Inc. at 1735 K Street, N.W., Washington, D.C. 20006. Additional information regarding the Company and the securities offered hereby is contained in Post-effective Amendment No. 2 to the Registration Statement on Form SB-2 (Registration No. 33-68932) of which this Prospectus forms a part, and the exhibits thereto filed with the Commission under the Securities Act of 1933, as amended (the "Securities Act"). The Registration Statement was filed by Alamar Biosciences, Inc., a California corporation which was renamed AccuMed International, Inc. and reincorporated in the State of Delaware effective December 29, 1995. Pursuant to Rule 411 under the Securities Act, the Company hereby adopts the Registration Statement as its own for all purposes under the Securities Act. For further information pertaining to the Company and the securities offered hereby, reference is made to Post-effective Amendment No. 2 to the Registration Statement and the exhibits thereto, which may be inspected without charge at, and copies may be obtained at prescribed fees from, the office of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549. The Company furnishes shareholders with annual reports containing audited financial statements and other periodic reports as the Company may deem to be appropriate or as required by law or the rules of the National Association of Securities Dealers, Inc. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE The following documents which have heretofore been filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated by reference herein and shall be deemed to be a part hereof: (1) The Company's Annual Report on Form 10-KSB for the year ended September 30, 1995. (2) The Company's Current Report on Form 8-K filed with the Commission on January 16, 1996. (3) The Company's Current Report on Form 8-K filed with the Commission on January 17, 1996. (4) The Company's Current Report on Form 8-K filed with the Commission on January 19, 1996. (5) The Company's Amendment No. 1 to the Current Report on Form 8-K/A filed with the Commission on January 24, 1996. -3- 4 (6) The Company's Transition Report on Form 10-KSB for the transition period ended December 31, 1995. (7) The Company's Quarterly Report on Form 10-QSB for the quarter ended March 31, 1996. (8) The description of Common Stock contained in the Company's Registration Statement on Form 8-A filed with the Commission on September 18, 1992 by which the Common Stock of the Company was registered under Section 12 of the Exchange Act, and the description of the Common Stock incorporated therein by reference to the Registration Statement on Form S-1 (Regis. No. 33-48302) filed with the Commission on June 3, 1992 and amended on June 25, 1992, July 23, 1992 and September 10, 1992, under the caption "Description of Securities" therein. (9) The description of the Common Stock contained in the Company's Amendment No. 1 to Registration Statement on Form 8-A/A filed with the Commission on January 2, 1996. All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Prospectus and prior to the termination of this Offering shall be deemed to be incorporated by reference in this Prospectus and to be a part hereof from the date of filing of such documents. Any statement incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus. The Company will provide without charge to each person to whom this Prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference in this Prospectus (not including exhibits and other information that is incorporated by reference unless the exhibits are themselves specifically incorporated by reference). Requests for such documents should be directed to AccuMed International, Inc., located at 920 N. Franklin Street, Suite 402, Chicago, Illinois 60610, Attn: Mark L. Santor, Chief Financial Officer, telephone (312) 642-9200. The following are trademarks of the Company: the "Alamar" logo and name, READar(TM), PIPETar(TM), alamarBlue(TM), AccuMed, Inc., AccuMed International, Inc., AccuMap(TM), Sensititre, SensiTouch(R), SensiLink(TM), Aris(TM), JustOne(TM), MicroBact, Sensi-Cal(TM), Amco AEPA-1(R) and Diascan. The Company's address is 920 N. Franklin Street, Suite 402, Chicago, Illinois 60610, and its telephone number is (312) 642-9200. -4- 5 PROSPECTUS SUMMARY THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED INFORMATION APPEARING ELSEWHERE IN THIS PROSPECTUS AND IN THE INFORMATION AND DOCUMENTS INCORPORATED BY REFERENCE HEREIN. THE STATEMENTS THAT ARE NOT HISTORICAL FACTS OR STATEMENTS OF CURRENT STATUS CONTAINED IN THIS PROSPECTUS ARE FORWARD-LOOKING STATEMENTS (AS DEFINED IN THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995) THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING, BUT NOT LIMITED TO, THE RISKS SET FORTH IN "RISK FACTORS." THE COMPANY AccuMed International, Inc. (Nasdaq Symbol: ACMI) (the "Company" or "AccuMed International") designs, manufactures and markets healthcare diagnostic and screening products for the clinical laboratory, pharmaceutical and veterinary segments of the healthcare industry. The Company's products service both the microbiology and cytopathology segments of the worldwide laboratory diagnostics market. AccuMed International is headquartered in Chicago, with manufacturing facilities in Cleveland, Ohio and, through its wholly-owned subsidiary, the United Kingdom. BACKGROUND; MERGER WITH ACCUMED, INC. The Company was incorporated in June 1988 under the name "Alamar Biosciences, Inc." under the laws of the State of California (the "Former Alamar"). On December 29, 1995, the merger of AccuMed, Inc., an Illinois corporation, with and into the Company (the "Merger") was consummated pursuant to an Agreement and Plan of Reorganization dated as of April 21, 1995 with AccuMed, Inc., as amended (the "Merger Agreement"). Also effective on such date, the Company was reincorporated under the laws of the State of Delaware, its name was changed to AccuMed International, Inc., and the trading symbols for its Common Stock and Warrants were changed from "ALMR" and "ALMRW" to "ACMI" and "ACMIW," respectively. Pursuant to the Merger Agreement the Company issued 6,178,104 shares of Common Stock and options to purchase an aggregate of 1,000,000 shares of Common Stock to the former holders of AccuMed, Inc. stock and former AccuMed, Inc. management, respectively. Pursuant to the Merger, the Company acquired its wholly-owned subsidiary, AccuMed International, Ltd., an English registry company ("AccuMed UK"). Prior to the Merger, the Company's business consisted of manufacturing and marketing in vitro (i.e., outside the body) diagnostic testing products for hospitals and reference laboratories, instruments for the interpretation and data management of the results of such products, and a non-toxic indicator dye for the detection of cell growth (such products are referred to collectively as the "Alamar Product Line"). The Company has also generated revenue from contract research projects, although no such revenue is being generated currently. The Company has a limited operating history and limited revenues from product sales to date. AccuMed, Inc. was incorporated in February 1994 under the laws of the State of Illinois. Prior to the Merger, AccuMed, Inc. was in the business of designing, developing and marketing products for the microbiology and cytopathology segments of the hospital and laboratory diagnostic market. AccuMed, Inc.'s strategy had been to seek to acquire companies with products or designs that reduce or potentially reduce costs and improve or potentially improve the quality and efficiency of laboratory diagnosis. In February 1995, AccuMed, Inc. acquired AccuMed UK and its business as well as certain U.S. assets from Radiometer America, Inc. (the products of AccuMed UK are collectively referred to as the "Sensititre Product Line"). Until such acquisition, AccuMed, Inc. had no revenues and operations consisted of a limited amount of research and development. BUSINESS OF THE COMPANY AccuMed International is targeting the cytopathology market with its proprietary automated cell -5- 6 image analysis product line for reading PAP smears and other cytology materials. The system consists of an interactive computer-controlled slide handling and data management system and an automatic cell analysis system which analyzes cells by screening slides for potential abnormalities. All systems are modular which permits them to be incorporated into more advanced, fully-automated systems if and when such systems become available. AccuMed International's microbiology product line includes a series of Minimum Inhibitory Concentration ("MIC") and identification ("ID") panels and a range of automated instruments used to identify infectious organisms and determine susceptibility to antimicrobial agents. The use of MIC/ID testing by hospitals and laboratories allows physicians to diagnose the proper treatment earlier, potentially shortening patient hospital stays. CYTOPATHOLOGY DIVISION PAP smear screening is conducted by specially trained and licensed cytotechnologists who by federal law are permitted to inspect no more than between 80 to 100 slides a day in search of abnormal cells. The clinical laboratory services market is currently experiencing a shortage of qualified cytotechnicians, and an increasing volume of cytologic tests to be processed. Recognizing the need to provide tools to aid in productivity and quality while reducing overall costs for this market, AccuMed International has developed an automated slide handling data management system, and acquired and developed an automated image cell analysis technology, the AcCell(TM) system. ACCELL(TM) PRODUCTS. Marketed under the name AcCell(TM), the Company offers cytopathology products that range from a fully automated slide handling system to interactive cell analysis systems, all supported by an integrated data management system. The AcCell(TM) system was initially developed for PAP smear analysis, however, management believes that the system has a broad range of cytopathology, pathology and histology applications beyond cervical PAP smear screening. All systems are modular and allow for migration to more advanced, fully automated systems. The AcCell(TM) system accepts conventionally stained slides, reviews the entire slide and automatically identifies any areas that require human review. The coordinates of all suspicious areas can be electronically retained for easy access and reference by the lab technician. Some AcCell(TM) models are designed to use digital imagery to scan specimen slides. At each inspection point a digital image is created and analyzed by the AcCell(TM) system using proprietary software, hardware and image analysis systems. AUTOMATIC SLIDE HANDLING SYSTEM. The AcCell(TM) products include a software and data management package designed to be used in conjunction with laboratory microscopes. As the slides move through the microscope, a technician can observe the slide through a high resolution color video monitor or microscope, thus avoiding use of the microscope, which can be strenuous. As a system or individual component, the auto slide handling device offers additional capacity, bar coding, digital storage of information, identification and retrieval capabilities and auto focus capabilities. In addition, the device can assist the technician in locating the exact location of abnormalities and fits with all commonly used cytology/pathology laboratory microscopes. The system does not require FDA approval, and management expects to begin marketing the Automatic Slide Handling System in the third quarter of 1996. ACCELL(TM) 3000. The AcCell(TM) 3000 is a series of productivity enhancement tools to be used for pre-screening conventionally prepared PAP smear specimens. The purpose of the pre- screening is to detect areas of the slide that are either vacant or contain clumps of material or blood which cannot be interpreted by the technician. The resulting computer map produced by the AcCell(TM) 3000 system is designed to guide the technician to only those portions of the slide which may contain abnormal cells. A technician can access this map through a database and follow the map by using the AcCell(TM) 2000 instrument. -6- 7 Pre-market approval by the FDA is required prior to any sales in the United States of the AcCell(TM) 3000 system. If such approval is obtained (of which there can be no assurance), management anticipates that the Company will hire sales specialists targeting geographical regions in the U.S., as well as several representatives responsible for education, training and overall support. The Company anticipates initiating marketing programs with major laboratories and hospitals, as well as small independent laboratories to increase sales of various systems. Management expects the Company to initiate clinical testing in late 1996. MICROBIOLOGY DIVISION The Alamar Product Line and the Sensititre Product Line together provide a range of complementary products to service the susceptibility and identification segments of the laboratory diagnostic marketplace. These product lines target both the high and low end volume users within the laboratory diagnostics market. SENSITITRE PRODUCT LINE. AccuMed UK with its Sensititre Product Line is a leader in veterinary and pharmaceutical new drug development susceptibility and identification testing. AccuMed UK was one of the first companies to introduce a range of systems for antimicrobic sensitivity testing utilizing microwell plate technology. The patented process developed by AccuMed UK has the ability to "dry-down," which secure, antimicrobics in the well of the microplate without loss of biological activity. The Sensititre Product Line consists of four principal instruments, each of which uses compatible technologies, and allows customers to upgrade. Such products incorporate a range of accessories including substrate strips, dosing heads, broths, and test plates for both susceptibility and identification applications. The Sensititre Product Line's microplate technology is based on AccuMed UK's patented dry-form 96 well microwell plates. Microwell plates were developed for susceptibility testing and can be manufactured both to a standard configuration, and customer specification. These products include gram negative and gram positive auto-identification plates. The Sensititre Product Line microplates include the following. JUST ONE STRIP. JustOne,(TM) is a single row of wells that can be used to test one antibiotic rather than using an entire plate. This technology was developed in conjunction with pharmaceutical companies to assist in the marketing and product launching efforts for a new drug. AUTOREADER. The AutoReader is a computerized, self-contained single excitation/detection wavelength fluorimeter, designed to rapidly measure intensity levels of fluorescence from automated microbiology test plates. ARIS(TM). ARIS(TM) is a totally automated plate handling, incubating and reading module that offers robotic processing of testing plates. ARIS(TM) has a capacity of 64 plates, of any type and combination of MIC/Breakpoint and Autoidentification. For use in larger laboratories, ARIS(TM) can be expanded by linking multiple units to the single host computer. SENSITITRE AUTOMATED MICROBIOLOGY SYSTEM ("SAMS"). SAMS is a sophisticated data management system which provides a wide range of data tracking and reporting capabilities in connection with the Sensititre MIC/ID Product line. ALAMAR PRODUCT LINE. A MIC/ID test panel is a clinical diagnostic system for the identification of infectious organisms, and the determination of the organism's susceptibility to antimicrobial agents at a variety of minimum inhibitory concentrations of antibiotics. The use of MIC/ID testing by hospitals and -7- 8 laboratories allows physicians to diagnose the proper treatment earlier, potentially shortening patient hospital stays. Also, by having a choice of antibiotics, the physician can choose the least expensive and/or the most compatible antimicrobial treatment for the patient. The Alamar Product Line's manual MIC/ID testing system is a proprietary disposable test kit system to diagnose the most effective type and dosage of antibiotics in cases involving bacterial infection and to identify the bacterium suspected of causing such infection. The manual MIC/ID testing systems incorporate the Company's proprietary alamarBlue(TM) technology. alamarBlue(TM) is a colorimetric interpretation which measures oxidation by producing a distinctive color change in order to indicate the proliferation of cells. SEMI-AUTOMATED READING PRODUCTS. In order to compete in other segments of the MIC/ID testing products market, the Company has developed a semi-automated reading instrument ("READar(TM)"), and a related computerized data management system. READar(TM) is an automated panel reader. READar(TM)'s fluorescent reading produces highly sensitive, reproducible and accurate results in less than 20 seconds. The Alamar Product Line MIC/ID testing kits are designed to be read both manually and by the READar(TM). The Company supplies its customers with an internally developed software package and with personal computers purchased "off the shelf" for purposes of management of the data generated by the READar(TM). No FDA marketing clearance is required to market the Company's software package in the U.S. The list price of a complete system, including the READar(TM) and the Company's data management system, is $30,000. TURN-KEY LABORATORY SERVICES GROUP. In addition to selling susceptibility/ID systems, AccuMed International has established a laboratory services group to provide "turn-key" antibiotic drug development and testing services for major pharmaceutical manufacturers. The group has contracts with approximately three pharmaceutical companies. ALAMARBLUE(TM) LICENSE AGREEMENT WITH BECTON DICKINSON alamarBlue(TM) is a non-toxic, water-soluble indicator dye which measures cell growth for in vitro testing. alamarBlue(TM) is a "reagent" (i.e. a substance used to detect and measure other substances) that is designed to be used in place of established reagents such as MTT, XTT, or neutral red reagents. The reagent can be interpreted visually due to the color change, or even more precisely using an instrument to measure the accompanying fluorescent response. On October 11, 1995, the Company entered into a License Agent (the "License Agreement") with Becton Dickinson & Co., Inc. ("Becton") pursuant to which the Company granted Becton a semi-exclusive, worldwide license of the Company's alamarBlue(TM) technology for a specific field of use. Pursuant to the License Agreement, Becton has been granted rights in and to all of the Company's alamarBlue(TM) technology and related trade secrets, know-how and patent rights (the "Licensed Technology"). Such license is exclusive to Becton; however, the license permits the Company to continue to practice all rights in the Licensed Technology, subject to certain restrictions on the Company's ability to engage in significant transactions with substantial competitors of Becton. The license is limited to certain applications in the microbiology market. Becton is obligated to pay royalties on net sales of any product which encompasses or incorporates the Licensed Technology for five years, subject to certain conditions and restrictions. As of the date of this Prospectus, a total of $3,500,000 in license fees has been received from Becton by the Company, of which $500,000 will be creditable against future royalties. INTELLECTUAL PROPERTY -8- 9 On March 26, 1996, the U.S. Patent and Trademark Office (the "PTO") issued to the Company Patent No. 5,501,959 in response to the Company's patent application entitled "Antibiotic and Cytotoxic Drug Susceptibility Assays Using Resazurin and Poising Agents" (the "AccuMed Patent"). The patent application filed by Michael Lancaster in 1989 and assigned to the Company. The AccuMed Patent provides patent protection for a portion of the Company's technology when used in conjunction with a "poising" agent used to stabilize the bacterial susceptibility process. The European Patent office has issued to the Company a notice of intent to grant a European patent relating to the AccuMed Patent. As a result of the Merger, the Company has obtained certain licenses on several U.S. and foreign patents and other intellectual property rights regarding aspects of the technology embodied in the Sensititre Product Line by virtue of the acquisition of AccuMed UK as a wholly-owned subsidiary. Between January 1994 and December 1995, AccuMed, Inc., filed or was assigned and aggregate of six U.S. patent applications which have been acquired by the Company as a result of the Merger. The products or technologies covered by such patent applications include blood culture, AcCell(TM) 2000 and AcCell(TM) 3000. The Company has also applied during 1996 for six additional U.S. patents relating to the optical imaging technology acquired in the Merger. The Company was advised in March 1996 that two the applications relating to blood culture have been allowed; management anticipates that such patents will issue in 1996. There can be no assurance that the aforementioned patents and licenses will adequately protect the Company from potential infringers. In addition, since patent applications in the U.S. are maintained in secrecy until patents issue, and since publications of discoveries in the scientific or patent literature tend to lag behind actual discoveries by several months, the Company cannot be certain that it was the first creator of inventions covered by pending patent applications or that such companies were the first to file patent applications for such inventions, and there can be no assurance that patents currently in application will ever be issued. On November 14, 1994, the Company filed a civil action in U.S. District Court for the Eastern District of California (the "Complaint") against Difco Laboratories, Inc. and Pasco Laboratories, Inc. (collectively, "Difco") seeking compensatory damages in excess of $25 million, punitive damages, an injunction against the further use and/or disclosure of the Company's trade secrets and confidential information, and for a constructive trust to transfer U.S. Patent No. 5,164,301 (the "301 Patent") to the Company. The Complaint alleged that Difco and a former employee of Difco were issued the 301 Patent on November 17, 1992 by misusing proprietary information that Difco personnel misappropriated from the Company in violation of a June 3, 1988 Confidentiality and Non-Use Agreement between the Company and Difco (the "Confidentiality Agreement"). The Company's U.S. patent application was filed in January 1989, and the Company believes that the application for the 301 Patent issued to Difco was filed in June 1990. On February 27, 1996, the Company entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") in connection with the Complaint. Pursuant to the Settlement Agreement the parties have settled the controversies between them raised in the Complaint and related civil actions and the Complaint and related civil actions were dismissed by mutual consent and the order of the court on March 11, 1996. The terms of the Settlement Agreement are confidential and may not be disclosed publicly, except as required by law or generally accepted accounting principles, without the mutual agreement of the parties. On May 2, 1995, the Company received notice that MicroScan, Inc. ("MicroScan"), a wholly-owned subsidiary of Dade International, Inc., filed an intervention complaint with the court against both the Company and Difco, which alleged that one of the Company's founders misappropriated confidential information of MicroScan while an employee of MicroScan prior to co-founding the Company in 1988, and used such information to develop the Company's technology. On October 13, 1995, summary judgment was granted in favor of the Company dismissing the MicroScan intervention complaint with prejudice. Microscan did not appeal the judgment. On February 23, 1996, the court granted the -9- 10 Company's motion that Microscan be required to pay the Company's attorneys fees of approximately $120,000 on the basis that Microscan's intervention complaint was made in bad faith. Despite settlement of the controversies with Difco and entry of summary judgment against Microscan, there can be no assurances that the Company will not become a party to future litigation involving other parties in connection with its intellectual property rights. RISK FACTORS The statements that are not historical facts or statements of current status contained in this Prospectus are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties, including, but not limited to, the risks set forth in "Risk Factors." The decision of whether to make an investment in the Common Stock involves an analysis of certain risks, including but not limited to, the risk factors set forth in this Prospectus. Each potential investor is urged to carefully consider the risks inherent in the recently consummated Merger, the Company's significant and continuing operating losses, the regulatory environment in which the Company operates, volatility of the Company's stock price, and the uncertainty of the cost of integration and consolidation of the recently merged companies. See "Risk Factors." -10- 11 RISK FACTORS The securities offered hereby involve a high degree of risk, including, but not necessarily limited to, the risk factors described below. Each prospective investor should carefully consider the following risk factors inherent in and affecting the business of the Company and this Offering before making an investment decision. The statements that are not historical facts or statements of current status contained in this Prospectus are forward-looking statements that involve risks and uncertainties including, but not limited to, the factors set forth below. POSSIBLE NEED FOR ADDITIONAL FINANCING. The Company anticipates that it will be required to obtain additional financing during the next 12 months to successfully carry out its business plan, and there can be no assurances that such funding will be available. If the Company is unable to raise additional funding, current resources will be reallocated and appropriate reductions will be made to the business plan. Of the approximately $2,400,000 of accounts payable as of March 31, 1996, approximately $1,000,000 represents amounts payable for over 30 days. Amounts owed to various vendors and suppliers are subject to late charges of approximately 1.5% per month. In the event the Company is unable to increase cash resources, significant demand on payables in excess of cash resources could cause the Company to liquidate assets, issue additional equity securities, curtail existing programs or make other arrangements that could have a material adverse effect on the business and prospects of the Company. Future design, development, testing and FDA submission costs will continue to be significant with respect to products not currently marketed, and the Company will also have significant capital requirements associated with marketing its current products. The Company has been substantially dependent on the private placements of its debt and equity securities and the proceeds of its initial public offering of securities consummated in October 1992 (the "IPO") to fund such requirements. Such private placements and the IPO have raised approximately $20,483,000 in aggregate gross proceeds. There can be no assurances that the Company will be able to obtain additional financing, or that, if available, such additional financing would be on terms acceptable to the Company. LIMITED RELEVANT OPERATING HISTORY; SIGNIFICANT OPERATING LOSSES; ACCUMULATED DEFICIT; UNCERTAINTY OF COSTS OF INTEGRATION AND CONSOLIDATION. Although the Company was formed in 1988 (as Alamar Biosciences, Inc.), until early 1994 the Company was engaged primarily in research and development and prior to the Merger had not realized any significant revenues from product sales. AccuMed, Inc. was incorporated in February 1994 and in February 1995 acquired AccuMed UK and its business as well as certain U.S. assets from Radiometer America, Inc. Until such acquisition, AccuMed, Inc. had no revenues and operations consisted of a limited amount of research and development. Accordingly, although AccuMed UK had a significant operating history and revenue from sales, AccuMed, Inc. had very limited operating history prior to the Merger. Upon consummation of the Merger on December 29, the operations of the Former Alamar and AccuMed, Inc. were combined and the resulting company began to manufacture and sell both the Alamar Product Line and the Sensititre Product Line. According, the combined company resulting from the Merger has a limited relevant operating history upon which an evaluation of the Company's prospects can be made. Such prospects must be considered in light of the risks, expenses and difficulties frequently encountered in the establishment of a new business in a continually evolving industry characterized by an increasing number of market entrants and intense competition; the risks, expenses and difficulties encountered in the shift from development to commercialization of new products based on innovative technology; and the possible risks and expenses associated with integrating the operations of the two recently merged companies. To date, the Company has incurred significant operating losses in each fiscal quarter since its inception. For the years ended September 30, 1993, 1994 and 1995, and the three months ended December 31, 1995 the Company's operating losses were $3,192,039, $3,146,476, $3,707,391 and $5,662,194, respectively and, at March -11- 12 31, 1996, the Company had an accumulated deficit of $25,410,621. Such losses are continuing and are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. Further, there can be no assurance that the Company will be able to implement successfully its operating strategy, generate increased revenues or ever achieve profitable operations. The costs of integration and consolidation of the recently merged companies as a single enterprise could prove substantial and the Company may be required to raise additional funds to cover such costs. There can be no assurance that the integration and consolidation of the recently merged companies into a single entity will not face unforseen problems which could materially increase the cost and delay the timing of such integration and consolidation. INDEBTEDNESS. The Company has indebtedness in the currently outstanding principal amount of $555,000 evidenced by certain promissory notes held by First Bank and Trust Company of Illinois ("First Bank") which are payable on the earlier of upon demand by First Bank and April 30, 1996. The Company attempted to repay in full the amounts owed to First Bank prior to April 30, 1996, but such payment was rejected due to a dispute regarding fees payable to First Bank. As of the date of this Prospectus, the Company has not yet resolved such disputed amounts although negotiations are underway. And, upon agreement of such disputes, the Company plans to repay the notes. Such failure to pay constitutes an event of default, however, First Bank has not sought to enforce available remedies, including foreclosing on the Certificates of Deposit of the Company in the aggregate amount of $310,000 and other assets of the Company which are pledged to secure the Company's obligations to First Bank in order to satisfy the indebtedness. There can be no assurances that First Bank will forebear from foreclosing prior to repayment, if any. PROTECTION OF INTELLECTUAL PROPERTY. On March 26, 1996, the U.S. Patent and Trademark Office issued to the Company Patent No. 5,501,959 in response to the Company's patent application entitled "Antibiotic and Cytotoxic Drug Susceptibility Assays Using Resazurin and Poising Agents" (the "AccuMed Patent"). The patent application filed by Michael Lancaster in 1989 and assigned to the Company. The AccuMed Patent provides patent protection for a portion of the Company's technology when used in conjunction with a "poising" agent used to stabilize the bacterial susceptibility process. The European Patent office has issued to the Company a notice of intent to grant a European patent relating to the AccuMed Patent. Despite issuance of the AccuMed Patent there can be no assurances that the AccuMed Patent will afford the Company commercially significant protection of the covered technologies. As a result of the Merger, the Company has obtained certain licenses on several U.S. and foreign patents and other intellectual property rights regarding aspects of the technology embodied in the Sensititre Product Line by virtue of the acquisition of AccuMed UK as a wholly-owned subsidiary. Between January 1994 and December 1995, AccuMed, Inc., filed or was assigned and aggregate of six U.S. patent applications which have been acquired by the Company as a result of the Merger. The products or technologies covered by such patent applications include blood culture, AcCell(TM) 2000 and AcCell(TM) 3000. The Company has also applied during 1996 for six additional U.S. patents relating to the optical imaging technology acquired in the Merger. There can be no assurance that the aforementioned patents and licenses will adequately protect the Company from potential infringers. In addition, since patent applications in the U.S. are maintained in secrecy until patents issue, and since publications of discoveries in the scientific or patent literature tend to lag behind actual discoveries by several months, the Company cannot be certain that AccuMed, Inc. or AccuMed UK was the first creator of inventions covered by pending patent applications or that such companies were the first to file patent applications for such inventions, and there can be no assurance that patents currently in application will ever be issued. The Company may, in the future, file additional patent applications; however, there can be no -12- 13 assurances that the Company will be successful in obtaining approval of any future patent applications it files with respect to its technologies. On November 14, 1994, the Company filed a civil action in U.S. District Court for the Eastern District of California (the "Complaint") against Difco Laboratories, Inc. and Pasco Laboratories, Inc. (collectively, "Difco") seeking compensatory damages in excess of $25 million, punitive damages, an injunction against the further use and/or disclosure of the Company's trade secrets and confidential information, and for a constructive trust to transfer U.S. Patent No. 5,164,301 (the "301 Patent") to the Company. The Complaint alleged that Difco and a former employee of Difco were issued the 301 Patent on November 17, 1992 by misusing proprietary information that Difco personnel misappropriated from the Company in violation of a June 3, 1988 Confidentiality and Non-Use Agreement between the Company and Difco (the "Confidentiality Agreement"). The Company's U.S. patent application was filed in January 1989, and the Company believes that the application for the 301 Patent issued to Difco was filed in June 1990. On February 27, 1996, the Company entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") in connection with the Complaint. Pursuant to the Settlement Agreement the parties have settled the controversies between them raised in the Complaint and related civil actions and the Complaint and related civil actions were dismissed by mutual consent and the order of the court on March 11, 1996. The terms of the Settlement Agreement are confidential and may not be disclosed publicly, except as required by law or generally accepted accounting principles, without the mutual agreement of the parties. On May 2, 1995, the Company received notice that MicroScan, Inc. ("MicroScan"), a wholly-owned subsidiary of Dade International, Inc., filed an intervention complaint with the court against both the Company and Difco, which alleged that one of the Company's founders misappropriated confidential information of MicroScan while an employee of MicroScan prior to co-founding the Company in 1988, and used such information to develop the Company's technology. On October 13, 1995, summary judgment was granted in favor of the Company dismissing the MicroScan intervention complaint with prejudice. Microscan did not appeal the judgment. On February 23, 1996, the court granted the Company's motion that Microscan be required to pay the Company's attorneys fees of approximately $120,000 on the basis that Microscan's intervention complaint was made in bad faith. Despite settlement of the controversies with Difco and entry of summary judgment against Microscan, there can be no assurances that the Company will not become a party to future litigation involving other parties in connection with its intellectual property rights. The Company also relies for protection of its intellectual property on trade secret law and nondisclosure and confidentiality agreements with its employees, consultants, distributors, researchers and advisors. There can be no assurances that such agreements will provide meaningful protection for the Company's trade secrets or proprietary know-how in the event of any unauthorized use or disclosure of such trade secrets or know-how. In addition, others may obtain access to or independently develop technologies or know-how similar to that of the Company. The Company's success will also depend on its ability to avoid infringement of patent or other proprietary rights of others. The Company is not aware that it is infringing any such rights of a third-party, nor is it aware of proprietary rights of others for which it will be required to obtain a license in order to develop its products. However, there can be no assurances that the Company is not infringing proprietary rights of others, or that the Company will be able to obtain any technology licenses it may require in the future. UNCERTAINTY OF MANUFACTURING. The Company's manufacturing facility in Sacramento, California, -13- 14 was closed effective August 31, 1995. From July 1, 1995 through consummation of the Merger on December 29, 1995, the Company's products were manufactured in AccuMed UK's Grinstead, U.K. facility pursuant to a Manufacturing and Supply Agreement between the Company and AccuMed UK (then a wholly-owned subsidiary of AccuMed, Inc., which became a wholly-owned subsidiary of the Company as a result of the Merger). Upon consummation of the Merger on December 29, 1995, the Company acquired AccuMed UK's manufacturing facility near London, England. The Company has had no experience operating a facility in the United Kingdom and the Company's ability to successfully operate such a facility will depend on it's ability to hire and retain skilled management, production, engineering and other personnel to operate the facility. Since consummation of the Merger, the Alamar Product Line and the Sensititre Product Line are being manufactured at AccuMed UK's United Kingdom facility acquired as a result of the Merger. While it is expected that consolidation of AccuMed, Inc's and the Company's manufacturing operations may result in certain economies of scale, there can be no assurances that the Company's products will ever be manufactured in a cost-effective manner. The Company's Cytopathology Division has only recently developed the AcCell(TM) system that uses certain optical image technology and automated cell image analysis to analyze slides that contain biological material such as PAP smears. Sales and marketing of the AcCell(TM) products have not yet begun. There can be no assurances that the Company will be able to enter into arrangements that will lead to the cost-effective manufacture of the AcCell(TM) products. In addition, the READar(TM) instrument and the PIPETar(TM) instrument are manufactured for the Company by the developers of such products or by other outside vendors. There can be no assurances that any of these developers or vendors will be able to manufacture Alamar Product Line's current and proposed automated reading or related products in a cost-effective manner. DELAYED OR UNSUCCESSFUL PRODUCT DEVELOPMENT. The Company's Cytopathology Division has only recently developed the AcCell(TM) systems which use certain optical image technology and automated cell image analysis to analyze slides that contain biological material such as PAP smears. The AcCell(TM) 3000 system requires pre-market approval from the FDA before sales may be made in the U.S. The Company anticipates commencing clinical testing of such product in late 1996 and anticipates submitting to the FDA a Pre-Market Application (PMA) or 510(k) Notification in the first quarter of 1997. There can be no assurances that such application will receive the necessary FDA approval. FDA approval is not required to sell the AcCell(TM) systems outside the U.S. The Sensititre Product Line's proposed blood culture products are in the development stage. There can be no assurances that any of such products will be fully developed or, if developed, that any of such products will receive the necessary FDA clearance or approval for marketing. Even if such clearance or approval is received, there can be no assurances that the proposed products will be accepted by the market. GOVERNMENT REGULATION. The Company's products and manufacturing processes are regulated by state and federal agencies, including the FDA and comparable agencies in certain states and other countries. United States regulatory requirements promulgated under the Federal Food, Drug, and Cosmetic Act (the "FD&C Act") provide that many of the Company's products may not be shipped in interstate commerce without prior authorization from the FDA. Such authorization is based on a review of the products' safety and effectiveness for their intended uses. Medical devices may be authorized by the FDA for marketing either pursuant to a premarket notification under Section 510(k) of the FD&C Act (a "510(k) Notification") or a PMA. The AcCell(TM) 3000 system may not be sold in the United States unless and until the Company has obtained FDA approval of a PMA submission. A PMA consists of information sufficient to establish independently that a device is safe and effective for its intended use. By statute, the FDA is required to -14- 15 respond to a PMA within 180 days from the date of its submission, however, the approval process usually takes substantially longer. Management estimates that the entire process of receiving pre-market approval of the complete system could take up to two years after submission of initial clinical data which management estimates will be submitted in early 1997. There can be no assurances that the Company will receive FDA marketing approval for such product or, if received, that such approval will not be withdrawn. Marketing of the AcCell(TM) 3000 system outside of the U.S. does not require FDA clearance or approval, and marketing of the AcCell(TM) 2000 throughout the world does not require and FDA submissions or approvals. The Company's Microbiology Division products for bacterial identification and susceptibility testing require the submission to the FDA of certain information prior to marketing to obtain a 510(k) Notification. Among other things, the Company must show that its products are "substantially equivalent" in terms of safety and effectiveness to existing products which are currently permitted to be marketed. The Company is permitted to begin marketing a product as to which it has submitted a 510(k) Notification at such time as the FDA issues a written finding of "substantial equivalence." Requests for additional information may delay the market introduction of certain of the Company's products and in practice initial approval of products can take substantially longer than the statutorily prescribed period of 90 days. All of the Company's current Alamar Product Line products that require FDA clearance have been cleared for marketing pursuant to 510(k) Notifications. The Alamar Product Line manual ID/MIC testing kits require the submission to the FDA of a 510(k) Notification with respect to each antibiotic to be tested by the Company's kits. To date, the Company has submitted 510(k) Notifications, and obtained findings of "substantial equivalence," for the Gram Negative Test Kit's testing of 32 out of the approximately 35 antibiotics commonly used to fight gram negative bacteria and for the Gram Positive Test Kit's testing of 21 out of the approximately 22 antibiotics commonly used to fight gram positive bacteria. The Company has also received marketing clearance for four separate 510(k) Notifications with respect to the READar(TM) system. The Company expects to submit applications to add individual antibiotics to the those previously cleared for the Gram Negative and Gram Positive Test Kits as the market warrants. However, the Company has experienced significant delays at the FDA in the recent past, and there can be no assurances that clearances will continue to be obtained as quickly as in the past or that the FDA will find "substantial equivalence" for these additional antibiotics. There can be no assurances that such a delay will not occur or that any of the Company's proposed future products not currently being marketed will be cleared or approved by the FDA. Failure to obtain marketing clearance or approval for proposed future products may have a material adverse effect on the Company. In addition, the Company is subject to certain FDA registration, record-keeping and reporting requirements, is obligated to follow FDA "Good Manufacturing Practices" ("GMP") regulations and is subject to periodic FDA inspection. The AccuMed UK manufacturing facility used to manufacture the Company's products meet applicable GMP guidelines and FDA regulations. There can be no assurances, however, that the facilities used to manufacture the Company's products will continue to meet GMP guidelines. Future changes in regulations or enforcement policies could impose more stringent requirements on the Company, compliance with which could adversely affect the Company's business. In connection with the Merger the required Notice of the relocation of manufacturing of the Alamar Product Line from Sacramento, California to East Grinstead, England has been provided to the FDA. TECHNOLOGICAL CHANGE AND COMPETITION. The Company's AcCell(TM) systems, if marketed abroad and if approved by the FDA and marketed in the U.S. (of which there can be no assurances), face competition from companies that are developing competing systems. The Company believes that other companies developing automated cytology products may possess greater development resources than the Company. The Company is currently aware of five companies that have systems in various stages of -15- 16 development for automated PAP smear screening. To date, management believes that none of these companies has received FDA approval for such products. Most of such companies are developing fully automated systems which are intended to eliminate or reduce the need for cytotechnicians who interpret smears visually. Such systems require stringent FDA testing. The market for the Company's microbiology products is highly competitive, and the Company competes with numerous well-established foreign and domestic companies, most of which possess substantially greater financial, technical, marketing, personnel and other resources than the Company and have established reputations for success in the development, sale and service of manual and/or automated in vitro diagnostic testing products. A significant portion of the ID/MIC testing market in the United States is controlled by two companies, Microscan and bioMerieux Vitek. These companies market a broad range of medically related products and have resources far greater than those of the Company. In addition, the Company is aware of several potential competitors with similar competitive advantages in markets that the Company intends to enter in the future. There can be no assurances that other technologies or products which are functionally similar to those of the Company are not currently available or under development, or that other companies with expertise and resources that would encourage them to attempt to develop and market competitive products will not develop new products directly competitive with the Company's products. In addition, the medical diagnostic products market is characterized by changing technology and evolving industry standards sometimes resulting in product obsolescence or short product life cycles. Accordingly, the ability of the Company to compete over the long-term will be dependent on the Company's ability to introduce its products to the marketplace in a timely manner and maintain a technically competent research and development staff which can continually enhance and improve such products and successfully develop and market new products. There can be no assurances that the Company will be able to keep pace with technological developments or that its products will not become obsolete. DEPENDENCE ON KEY EMPLOYEES. The Company believes that its success will depend to a significant extent upon the efforts and abilities of a small group of executive, scientific and marketing personnel, in particular Peter P. Gombrich the Company's Chief Executive Officer and Chairman of the Board. The loss of the services of one or more of these key personnel could have a material adverse effect on the Company. In addition, the Company's future success will depend upon its ability to continue to attract and retain qualified scientific and management personnel who are in great demand. There can be no assurances that the Company will be successful in attracting and retaining such personnel. POSSIBLE VOLATILITY OF STOCK AND WARRANT PRICES. The market price of the Company's securities may be highly volatile as there have been periods of extreme fluctuation in the stock market that, in many cases, were unrelated to the operating performance of, or announcements concerning, the issuers of the affected securities. Securities of issuers, such as the Company, having relatively limited capitalization and securities that are thinly-traded are particularly susceptible to change based on short-term trading strategies of certain investors. LACK OF DIVIDENDS. The Company has never paid cash or other dividends on its Common Stock and does not intend to pay cash or other dividends in the foreseeable future. AUTHORIZATION AND ISSUANCE OF PREFERRED STOCK. The Company's Certificate of Incorporation authorize the issuance of preferred stock with such designation, rights and preferences as may be determined from time to time by the Board of Directors. Accordingly, the Board of Directors is empowered, without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of the Company's Common Stock. Although the Company does not currently intend to issue any shares of its preferred stock, in the event of issuance, such shares could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of the Company. There can be no -16- 17 assurances that the Company will not, under certain circumstances, issue shares of its preferred stock. OUTSTANDING WARRANTS. As of the date of this Prospectus, there are outstanding immediately exercisable Warrants to purchase 6,041,260 shares of Common Stock at exercise prices ranging from $0.25 to $5.00 per share. To the extent that any such warrants are exercised, dilution in the ownership interests of the Company's shareholders may occur. SHARES ELIGIBLE FOR FUTURE SALE; REGISTRATION RIGHTS. As of the date of this Prospectus there are 18,913,234 shares of Common Stock outstanding. Of these, 1,571,123 shares of Common Stock included in the IPO and subsequent registration statements are freely tradeable without restriction or requirement of further registration under the Securities Act, unless such shares are held by "affiliates" of the Company (as that term is defined in the Securities Act and the regulations promulgated thereunder) and subject, in certain instances, to the prospectus delivery requirements under the Securities Act. The balance of the shares were sold by the Company in reliance on exemptions from the registration requirements of the Securities Act. Of such shares, approximately 1,273,000 shares are currently eligible for immediate sale in the public market, approximately 3,892,000 shares may be sold into the market upon compliance with Regulation S and the balance will become eligible at various times in the future. In addition the Company has granted certain demand and/or piggyback registration rights relating to a substantial portion of the restricted shares and a substantial number of shares of Common Stock underlying warrants issued by the Company. Any future exercise of such registration rights and sale of such securities will result in dilution in the interest of the Company's then existing shareholders. No prediction can be made as to the effect, if any, that future sales of additional shares of Common Stock or the availability of such shares for sale either pursuant to exercised registration rights or under Rule 144 or other applicable exemptions under the Securities Act will have on the market price of the Common Stock prevailing from time to time. Nevertheless, the possibility that substantial amounts of Common Stock may be sold in the public market may adversely affect prevailing market prices for the Common Stock and could impair the ability of the Company to raise capital through the sale of its equity securities. CONTROL OF THE BOARD OF DIRECTORS. As a result of the Merger, the Company's Board of Directors consists of Mr. Peter P. Gombrich, two individuals selected by AccuMed, Inc. (Messrs. Joseph Plandowski and Paul Lavallee), three individuals selected by Commonwealth Associates (a principal holder of the Company's warrants and the underwriter and placement agent in several offerings of the Company's securities), and American Equities Overseas, Inc. (which represents several principal shareholders of the Company) (Messrs. Jack Halperin, Leonard Schiller and Richard Corbin) and one individual selected by mutual consent of the other nominees (Dr. John H. Abeles). The Company's directors, executive officers and their affiliates own approximately 20.7 % of the outstanding shares of Common Stock. Such persons are thus able to exert significant influence over the affairs of the Company. -17- 18 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements give effect of the Merger of Alamar and AccuMed and the purchase of certain assets and the assumption of certain liabilities from Sensititre US and Sensititre UK by AccuMed on a purchase basis. The unaudited pro forma condensed combined statements of operations for the year ended September 30, 1995 and the three months ended December 31, 1995 assume that the Merger with AccuMed and the purchase of Sensititre US and Sensititre UK occurred on October 1, 1994. The pro forma adjustments are based on preliminary assumptions of the allocation of the purchase price and are subject to substantial revision once evaluation of the fair value of the assets and liabilities of AccuMed are completed. Actual purchase accounting adjustments may differ from the pro forma adjustments presented herein. THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS ARE NOT NECESSARILY INDICATIVE OF THE RESULTS THAT ACTUALLY WOULD HAVE OCCURRED IF THE MERGERS HAD BEEN COMPLETED ON THE ASSUMED DATES NOR ARE THE STATEMENTS INDICATIVE OF FUTURE COMBINED FINANCIAL POSITION OR EARNING. The pro forma condensed financial statements should be read in conjunction with the financial statements of Alamar for the fiscal year ended September 30, 1995 and the financial statements for the transition period ended December 31, 1995. -18- 19 ACCUMED INTERNATIONAL, INC (formerly ALAMAR BIOSCIENCES, INC. AND SUBSIDIARIES) PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED SEPTEMBER 30, 1995
Historical Historical ------------- ----------------------------------------------- Alamar AccuMed Sensititre US Sensititre UK year ended September 30, 1995 (1) (2) (2) ------------- ------------- ------------- ------------- (unaudited) (unaudited) (unaudited) Net Revenues $ 514,776 $ 2,609,233 $ 409,360 $ 639,561 Cost of revenues (1,431,187) (1,510,143) (247,860) (457,056) ------------- ------------- ------------- ------------- (916,411) 1,099,090 161,500 182,505 ------------- ------------- ------------- ------------- Operating Expenses General and Administration 2,094,890 1,040,083 208,420 74,589 Research and Development 386,882 453,277 0 88,872 Sales and Marketing 309,208 1,187,177 0 0 ------------- ------------- ------------- ------------- Total operating expenses 2,790,980 2,680,537 208,420 163,461 ------------- ------------- ------------- ------------- Income (Loss) from operations (3,707,391) (1,581,447) (46,920) 19,044 Interest income 7,949 12,930 0 0 Interest (expense) (46,657) (40,201) 0 0 Other income 32,566 1,308 0 0 Other (expense) (45,777) 0 0 0 ------------- ------------- ------------- ------------- Earnings (Loss) before income taxes (3,759,310) (1,607,410) (46,920) 19,044 Provision for income taxes 800 0 0 0 ------------- ------------- ------------- ------------- Net income (loss) $ (3,760,110) $ (1,607,410) $ (46,920) $ 19,044 ============= ============= ============= ============= Net loss per common and common equivalent share $ (0.59) $ (0.92) ============= ============= Weighted average shares outstanding 6,375,627 1,748,940 ============= ============= Pro Forma Pro Forma ------------------------------ ----------------------------- AccuMed AccuMed Alamar/ Alamar Sensitive as adjusted, for AccuMed as adjusted, for Adjustments the year ended Adjustments the year ended September 30, September 30, 1995 1995 (3) (4) ------------- ------------- ------------- ------------- (unaudited) (unaudited) (unaudited) (unaudited) Net Revenues $ (193,000)(A) $ 3,485,154 $ 0 $ 3,979,930 Cost of revenues 109,000 (B) (2,108,059) 0 (3,537,246) ------------- ------------- ------------- ------------- (84,000) 1,359,095 0 442,684 ------------- ------------- ------------- ------------- Operating Expenses General and Administration 100,000 (C) 1,423,092 284,570 (E) 3,602,552 Research and Development 0 542,149 0 929,031 Sales and Marketing 0 1,187,177 0 1,496,385 ------------- ------------- ------------- ------------- Total operating expenses 100,000 3,152,418 284,570 8,227,968 ------------- ------------- ------------- ------------- Income (Loss) from operations (184,000) (1,793,323) (284,570) (5,785,284) Interest income 0 12,930 0 20,679 Interest (expense) (35,475)(D) (75,676) 0 (122,333) Other income 0 1,308 0 33,874 Other (expense) 0 0 0 (45,777) ------------- ------------- ------------- ------------- Earnings (Loss) before income taxes (219,475) (1,854,761) (284,570) (5,898,841) Provision for income taxes 0 0 0 800 ------------- ------------- ------------- ------------- Net income (loss) $ (219,475) $ (1,854,781) $ (284,570) $ (5,899,441) ============= ============= ============= ============= Net loss per common and common equivalent share $ (1.06) $ (0.60) ============= ============= Weighted average shares outstanding 1,748,940 9,831,582 ============= =============
(1) includes the twelve months and nine months ended September 30, 1995 for AccuMed and Sensititre US/UK, respectively (2) includes the three months ended December 31, 1994, before the acquisitions by AccuMed. (3) AccuMed Consolidated includes AccuMed, Sensititre US, and Sensititre UK, Ltd. after purchase accounting adjustments (4) Alamar Consolidated includes Alamar Biosciences Inc., and AccuMed Consolidated after purchase accounting adjustments. Weighted average shares outstanding are 9,831,682 which represents 6,375,637 shares for Alamar before the merger plus the weighted average (3,456,055) of the 4,178,104 shares (6,178,104 shares per the merger agreement less 2,000,000 shares issued but subject to forfeiture) to be issued in connection with the AccuMed merger. The weighted average shares outstanding for AccuMed gives effect to the shares issued by AccuMed during the year ended September 30,1995 using the exchange ratio of 1.98 to 1. The total shares outstanding at September 30, 1995 are 15,107,443 (10,929,339 shares of Alamar and 4,178,104 shares issued to AccuMed) which does not include the 2,000,000 shares issued but subject to forfeiture. -19- 20 ALAMAR BIOSCIENCES, INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED SEPTEMBER 30, 1995 ALAMAR BIOSCIENCES, INC., AND SUBSIDIARIES NOTES TO PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS SEPTEMBER 30, 1995 (UNAUDITED) (A) To eliminate intercompany sales from Sensititre UK to Sensititre US. (B) To eliminate intercompany profit from the cost of product sold from Sensititre UK to Sensititre US. (C) To reduce amortization expense ($20,000) for the amortization of the purchase price of AccuMed, Inc. in excess of the fair market value of acquired assets, less assumed liabilities, and transaction costs incurred with the Merger of AccuMed, Inc. amortized over a 10 year life, and to adjust amortization expense for Sensititre US and Sensititre UK. Adjustment to reflect a reasonable estimation ($120,000) of corporate overhead costs for the three months ended December 31, 1994 carve out period for Sensititre U.S. The estimate is based on a percentage of total sales of Radiometer America, Inc., (of which Sensititre U.S. was a division) to the Sensititre US product line. (D) To adjust interest expense for $35,475, assuming that the $430,000 loan to finance the Sensititre acquisition occurred on October 1, 1994. (E) To adjust amortization expense for the amortization of the purchase price of AccuMed, Inc. in excess of the fair market value of acquired assets, less assumed liabilities, and transaction costs incurred with the Merger of AccuMed, Inc. amortized over a 10 year life, and to adjust amortization expense for Sensititre US and Sensititre UK. -20- 21 ACCUMED INTERNATIONAL, INC. (FORMERLY ALAMAR BIOSCIENCES, INC. AND SUBSIDIARIES) PRO-FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 1995
Historical Pro-forma Pro-forma Pro-forma -------------- ------------ ----------- ----------- AccuMed International, AccuMed Inc. Pro-Forma Inc. (Acquiree) Adjustments Consolidated -------------- ------------ ----------- ------------ (audited) (unaudited) (unaudited) (unaudited) Net Revenues $100,130 $1,009,376 ($73,005) (A) $1,036,501 Cost of Revenues (338,730) (830,497) 71,892 (B) (1,097,335) ----------- ----------- -------- ---------- (238,600) 178,879 (1,113) (60,834) Operating Expenses General and Administration 1,418,797 758,066 0 2,176,863 Research and Development 3,997,600 338,178 0 4,335,778 Sales & Marketing 7,197 289,360 0 296,557 ----------- ----------- -------- ---------- Total Operating Expenses 5,423,594 1,385,604 0 6,809,198 ----------- ----------- -------- ---------- Income (Loss) from operations (5,662,194) (1,206,725) (1,113) (6,870,032) Interest Income 4,748 0 0 4,748 Interest (expense) (10,862) (1,948) 0 (12,810) Other (72,929) 0 0 (72,929) ----------- ----------- -------- ---------- Loss before income taxes (5,741,237) (1,208,673) (1,113) (6,951,023) Provision for income taxes 800 0 0 800 ----------- ----------- -------- ---------- Net loss ($5,742,037) ($1,208,673) ($1,113) ($6,951,823) =========== =========== ======== ========== Net loss per common share ($0.49) ($0.10) ($0.00) ($0.59) Weighted average shares outstanding 11,742,980 11,742,980 11,742,980 11,742,980
-21- 22 ACCUMED INTERNATIONAL, INC. (FORMERLY ALAMAR BIOSCIENCES, INC.) AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 1995 ACCUMED INTERNATIONAL, INC., AND SUBSIDIARIES NOTES TO PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS DECEMBER 31, 1995 (UNAUDITED) (A) To eliminate intercompany sales from AccuMed International Limited (UK) to AccuMed Inc. (US) (B) To eliminate intercompany profit from the cost of product sold from AccuMed International Limited (UK) to AccuMed Inc. (US) -22- 23 USE OF PROCEEDS The Company will not receive any proceeds from the sale of the Common Stock and/or Warrants by the Selling Securityholders. In the event that all of the shares of Common Stock offered by the Company hereby are issued pursuant to the terms of the 1993 Warrants, the Company would receive up to approximately $8,567,025 in net proceeds. The net proceeds of such issuances will be undesignated funds and will be used by the Company for, among other things, research and development, sales and marketing, manufacturing facility improvements and general corporate purposes. The Company has agreed to pay certain expenses in connection with this offering, currently estimated to be approximately $60,000. RECENT DEVELOPMENTS PROPOSED ACQUISITION OF ACCURON CORPORATION. The Company and Accuron Corporation, and Ohio corporation ("Accuron"), have agreed to the purchase by the Company of all assets of Accuron in consideration for the issuance of 100,000 shares of the Company's Common Stock. The assets to be acquired consist largely of U.S. and foreign patents in the areas of image analysis and automated cytology. The Company will not assume any liabilities of Accuron. Management anticipates that the transaction will be consummated during the second quarter of 1996. Such shares will have certain so-called "piggyback" registration rights. PRIVATE PLACEMENT OF SECURITIES. On May 23, 1996, the Board of Directors approved the terms of two proposed private placements of Common Stock of the Company. The Company has entered into an oral agreement with an institutional shareholder for the purchase by such shareholder of 166,667 shares of Common Stock at a purchase price of $6.00 per share for aggregate consideration of $1,000,000. Management anticipates that such transaction will be consummated by May 31, 1996. American Equities Overseas, Inc. has made an oral agreement with the Company to serve as placement agent on a best efforts basis in the proposed private placement to non-U.S. persons of approximately 83,333 shares of Common Stock at $6.00 per share for aggregate consideration of $500,000. Management anticipates that such transaction will be consummated by June 7, 1996. POSSIBLE REDEMPTION OF WARRANTS. The Company issued an aggregate of 2,702,905 Common Stock Purchase Warrants (the "Redeemable Warrants") in its initial public offering in 1992 and in private placements in 1993 [INCLUDING THE 574,905 WARRANTS OFFERED FOR SALE HEREBY BY THE SELLING SECURITYHOLDERS -- THIS GOES IN THE SB-2 ONLY]. The Company is entitled to redeem the Redeemable Warrants upon 60 days prior written notice to the warrantholders given at least 3 days after the closing sales price of the Common Stock has exceeded $7.50 per share for a minimum of 20 consecutive trading days. The Common Stock first closed trading above $7.50 per share on May 22, 1996. If the Common Stock continues to close above $7.50 per share for 20 consecutive trading days, the Company intends to give notice of redemption of the Redeemable Warrants. The redemption price is $0.25 per Redeemable Warrant. The exercise price of the Redeemable Warrants is $5.00 per share. Therefore, if the Common Stock continues to trade above $5.25 per share during the period after notice and prior to the redemption date, management anticipates that holders of Redeemable Warrants will elect to exercise their Redeemable Warrants prior to the redemption date. If all the Redeemable Warrants were exercised the Company would receive proceeds of approximately $13,500,000. FORWARD LOOKING STATEMENTS The statements that are not historical facts in this Prospectus are "forward looking statements" and as such involve risks and uncertainties including, but not limited to, the risks and uncertainties set forth under the caption "Risk Factors" elsewhere in this Prospectus. Such statements include the following specific statements": Page 6, paragraph 4, sentence 2; page 7, paragraph 2, last sentence; page 9, paragraph 3, sentence 5; page 13, paragraph 1; page 14, paragraph 2, last sentence and paragraph 3, sentence 3; page 15, h 2, sentence 9; and "Recent Developments." The above-referenced statements contained in this Prospectus are forward looking statements that involve a number of risks and uncertainties. In addition to the factors referenced above, among the other factors that could cause actual results to differ materially are the following: business conditions and growth in the health care diagnostic industry and general economy; competitive factors, such as rival manufacturers and products, and price pressures; inventory risks due to shifts in market demand; changes in product mix; difficulties encountered in the shift from development to commercialization of new products based on innovative technology; possible risks and costs associated with combining the operations of the Former Alamar, AccuMed UK and AccuMed, Inc. as a result of the Merger; and the risk factors listed from time to time in the Company's Securities and Exchange Commission reports and under the caption "Risk Factors" in this Prospectus. -23- 24 PRICE RANGE OF COMMON STOCK AND WARRANTS The Company's Common Stock and Warrants are traded in the over-the-counter market and quoted on Nasdaq under the symbols "ACMI" and "ACMIW," respectively. The tables below set forth the range of high and low closing prices for the Common Stock and Warrants as reported on Nasdaq in each completed quarter during the Company's two most recently completed fiscal years, the Transition Period, each completed quarter during the current fiscal year and a portion of the current quarter.
COMMON STOCK High Low ----- ----- 1994 Fiscal Year First Quarter .................................... $4.13 $2.13 Second Quarter ................................... 3.00 1.75 Third Quarter .................................... 2.75 1.00 Fourth Quarter ................................... 2.63 1.25 1995 Fiscal Year First Quarter .................................... 1.75 0.31 Second Quarter ................................... 1.75 0.50 Third Quarter .................................... 1.50 0.81 Fourth Quarter ................................... 1.50 0.75 Transition Period (1) Oct. 1, 1995 through December 31, 1995 ........... 1.69 1.00 1996 Fiscal Year (1) First Quarter .................................... 6.25 1.06 Second Quarter (through May 14, 1996) ............ 7.13 4.88
____________________________ (1) On December 31, 1995, the Company changed its fiscal year from October 1 through September 30 to January 1 through December 31. Therefore, the "Transition Period" includes October 1, 1995 through December 31, 1995. WARRANTS 1994 Fiscal Year First Quarter .................................. 0.81 0.38 Second Quarter.................................. 0.50 0.38 Third Quarter .................................. 0.75 0.25 Fourth Quarter ................................. 0.13 0.56 1995 Fiscal Year First Quarter .................................. 0.22 0.03 Second Quarter.................................. 0.41 0.09 Third Quarter .................................. 0.31 0.13 Fourth Quarter.................................. 0.16 0.09 Transition Period (1) Oct. 1, 1995 through December 31, 1995.......... 0.19 0.13 1996 Fiscal Year (1) First Quarter .................................. 1.81 0.25 Second Quarter (through May 14, 1996)........... 2.31 1.06
-24- 25 ____________________________ (1) On December 31, 1995, the Company changed its fiscal year from October 1 through September 30 to January 1 through December 31. Therefore, the "Transition Period" includes October 1, 1995 through December 31, 1995. On May 17, 1996 the closing price of the Common Stock and Warrants, respectively, as reported by Nasdaq was $7.13 per share and $2.31 per Warrant. At May 17, 1996, the Company had approximately 225 shareholders of record and estimates that it had approximately 560 beneficial owners. SELLING SECURITYHOLDERS COMMON STOCK. The following table sets forth certain information with respect to the beneficial ownership of shares of Common Stock by each of the Selling Securityholders as of the commencement of the Offering and May 17, 1996 (the "Reference Date") giving effect to the Offering. As of the Reference Date there were 18,913,234 shares of Common Stock outstanding.
Shares Beneficially(2) Shares Beneficially(2) Owned Prior to Offering Shares Owned After Offering Name of Selling ----------------------- Being ----------------------- Securityholder (1) Number Percent Offered Number Percent - - - ------------------ ------ ------- ------- ------ ------- Henry T. Wilson(3) 242,628(3) 1.27 % 1,429 0 * Northwood Ventures(4) 223,222 1.17 % 37,500 0 * Kenneth D. Miller(5) 136,392 * 3,004 192,000 * Mark L. Santor(6) 33,030 * 2,286 91,961 * Joel S. Kanter(7) 25,832 * 3,198 16,215 * Donald M. Earhart(8) 13,577 * 2,859 40,772 * Jack H. Halperin(9) 9,679 * 1,429 66,800 * Joseph L. Schocken(10) 7,978 * 1,429 14,645 * Northlea Partners Limited(11) 223,478 1.18% 29,478 256,129 1.33 % Cie Financiere de Rombas(12) 205,707 1.09% 43,350 162,057 * Charles J. Soderquist(13) 147,429 * 7,679 138,750 * BFG Bank Schweiz, A.G.(14) 60,000 * 30,000 30,000 * Clariden Bank(15) 50,000 * 25,000 25,000 * Maison Antoine Baud(16) 40,000 * 10,000 30,000 * Praktek Venture Fund(17) 27,046 * 2,383 24,663 * Christopher Myers(18) 22,878 * 7,626 15,252 * Frederick Myers, III(19) 22,878 * 7,626 15,232 * Cogeval, S.A.(20) 20,000 * 10,000 10,000 * Windy City, Inc.(21) 8,509 * 1,769 7,384 * Carol Levy(22) 8,450 * 2,383 6,067 * Connie Lannon(23) 8,354 * 2,286 6,068 * Chuck Schembra(24) 8,143 * 2,143 6,000 * Frederick and Christopher Myers(25) 6,510 * 1,302 5,208 *
-25- 26 Alan C. and Linda Alhadeff(26) 5,718 * 1,906 3,812 * Praktek Venture Fund II(27) 4,766 * 2,383 2,383 * Raymond Harkavy, M.D.(28) 3,429 * 1,143 2,286 * Lance D. and Dalia C. Nagel(29) 3,123 * 520 2,603 * Louise Maksymowicz(30) 1,874 * 312 1,562 * Leonard Levy(31) 513 * 171 342 * 52 Gift Share Recipients(32) 38,401 * 425 37,976 *
- - - -------------------------------------- * Represents less than 1%. (1) Unless otherwise noted, the Company believes that all persons named in the table have sole voting and investment power with respect to all shares of Common Stock beneficially owned by them. A person is deemed to be the beneficial holder of securities that can be acquired by such person currently or within 60 days Reference Date upon the exercise of warrants or options. Each beneficial owner's percentage ownership is determined by assuming that options or warrants that are held by such person (but not those held by any other person) and which are exercisable currently or within 60 days following the Reference Date have been exercised. (2) The percentages owned are based on a total of 18,913,234 shares of Common Stock outstanding on the Reference Date and assumes no exercise of Warrants. Shares owned prior to the Offering are the number of shares owned upon commencement of the Offering. Shares owned after the Offering include shares acquired subsequent to commencement of the Offering. (3) Includes 233,222 shares held of record before the Offering by Northwood Ventures. Henry T. Wilson, a director of the Company from March 1992 through April 21, 1995, is a Vice-President of Northwood Ventures. Mr. Wilson disclaims beneficial ownership of such shares. Shares owned prior to the Offering include rights to acquire 130,132 shares within 60 days of the Reference Date. (4) Shares owned prior to the Offering include 97,254 shares underlying warrants that are exercisable currently or within 60 days of the Reference Date. Henry T. Wilson, a former director of the Company, is Vice-President of Northwood Ventures. (5) Shares owned prior to the Offering include rights to acquire 133,388 shares s within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 165,000 shares within 60 days of the Reference Date. Mr. Miller was President of the Cytopathology Division of the Company from August 1995 until May, 1996. He served as Chief Executive Officer and a director of the Company form October 1989 until April 21, 1995 at which time he was appointed Senior Vice president of the Company. (6) Shares owned prior to the Offering include rights to acquire 30,744 shares within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 56,961 shares within 60 days of the Reference Date. Mr. Santor has been Chief Financial Officer of the Company since June 1991, Vice President, Fiance and Operations since November 1992 and Secretary since November 1994. (7) Shares owned prior to the Offering include rights to acquire 22,634 shares within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 16,215 shares within 60 days of the Reference Date. Mr. Kanter was a director of the Company from June 1991 through April 21, 1995. (8) Shares owned prior to the Offering include rights to acquire 7,859 shares within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 2,859 shares within 60 days of the Reference Date. Mr. Earhart was a director of the Company from May 1994 until December 29, 1995. -26- 27 (9) Shares owned prior to the Offering include rights to acquire 8,250 shares within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 36,800 shares within 60 days of the Reference Date. Mr. Halperin has been a director of the Company since June 1991 and served as Chairman of the Board from April through December 1995. (10) Shares owned prior to the Offering include rights to acquire 6,549 shares within 60 days of the Reference Date. Mr. Schocken was a director of the Company from November 1992 until April 1995. (11) Shares owned prior to the Offering include rights to acquire 38,049 shares within 60 days of the Reference Date. John H. Abeles, a director of the Company, is an affiliate of Northlea Partners Limited. (12) Shares owned prior to the Offering include rights to acquire 43,350 shares within 60 days of the Reference Date. (13) Shares owned prior to the Offering include rights to acquire 14,750 shares within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 7,500 shares within 60 days of the Reference Date.Dr. Soderquist was a director of the Company from December 1989 through October 27, 1994. (14) Shares held of record by American Securities Corporation for benefit of BFG Bank Schweiz, A.G. Shares owned prior to the Offering include rights to acquire 30,000 shares within 60 days of the Reference Date. (15) Shares owned prior to the Offering include rights to acquire 25,000 shares within 60 days of the Reference Date. (16) Shares owned prior to the Offering include rights to acquire 20,000 shares within 60 days of the Reference Date. (17) Shares owned prior to the Offering include rights to acquire 2,383 shares within 60 days of the Reference Date. (18) Shares owned prior to the Offering include rights to acquire 7,626 shares within 60 days of the Reference Date. (19) Shares owned prior to the Offering include rights to acquire 7,626 shares within 60 days of the Reference Date. (20) Shares owned prior to the Offering include rights to acquire 10,000 shares within 60 days of the Reference Date. (21) Shares owned prior to the Offering include rights to acquire 5,309 shares within 60 days of the Reference Date. Shares owned after the Offering include rights to acquire 3,750 shares within 60 days of the Reference Date.Joel S. Kanter was a director of the Company from June 1991 until April 21, 1994 and is President of Windy City, Inc. (22) Shares owned prior to the Offering rights to acquire 2,643 shares within 60 days of the Reference Date. (23) Ms. Lannon was Director of Sales and Marketing of the Company from until November 15, 1994. Shares owned prior to the Offering include rights to acquire 6,068 shares within 60 days of the Reference Date. (24) Mr. Schembra was Vice-President, Manufacturing, of the Company until November 15, 1994. Shares owned prior to the Offering include rights to acquire 6,000 shares within 60 days of the Reference Date. (25) Shares owned prior to the Offering include rights to acquire 1,302 shares within 60 days of the Reference Date. (26) Shares owned prior to the Offering include rights to acquire 1,906 shares within 60 days of the Reference Date. (27) Shares owned prior to the Offering include rights to acquire 2,383 shares within 60 days of the Reference Date. (28) Shares owned prior to the Offering include rights to acquire 1,143 shares within 60 days of the Reference Date. -27- 28 (29) Shares owned prior to the Offering include rights to acquire 520 shares within 60 days of the Reference Date. (30) Shares owned prior to the Offering include 1,562 shares currently held and rights to acquire an additional 312 shares within 60 days of the Reference Date. (31) Shares owned prior to the Offering include 342 shares currently held and rights to acquire an additional 171 shares within 60 days of the Reference Date. (32) Shares owned prior to the Offering include an aggregate of 425 shares currently held and rights to acquire an additional aggregate of 37,976 shares within 60 days of the Reference Date. The shares currently held represent shares gifted to 52 individuals by Kenneth D. Miller in 1994. No individual owns more than 50 shares. The rights represent options to purchase shares held by certain employees of the Company included among the gift recipients. WARRANTS. The following table sets forth the name of each beneficial owner of the Warrants being offered by each Selling Securityholder. Except as otherwise indicated, each holder set forth below owns no other Warrants other than those being offered hereby and, assuming sale of each of the Warrants offered hereby, each holder will own no Warrants after the Offering.
Warrants Name of Beneficial Owner Being Offered - - - ------------------------------- ------------- Microcap Growth Fund, Inc.(1) 250,000 Cie. Financiere de Rombas 43,350 BFG Bank Schweiz, AG(2) 30,000 Northlea Partners Limited(3) 28,049 Clariden Bank 25,000 Walnut Capital Corp. 22,000 Jack M. Ferraro 19,066 Maro Enterprises(4) 12,500 Cogeval, S.A. 10,000 Maison Antoine Baud 10,000 Christopher Myers 7,626 Frederick Myers, III 7,626 Charles J. Soderquist(5) 6,250 Donald M. Earhart 2,859 Carol Levy 2,383 Praktek Venture Fund 2,383 Praktek Venture Fund, II 2,383 Alan C. and Linda Alhadeff 1,906 Windy City, Inc.(6) 1,769 Frederick and Christopher Myers 1,302 Raymond Harkavy, M.D. 1,143 Lance D. and Dalia C. Nagel 520 Louise Maksymowicz 312 Leonard Levy 171
- - - ------------- (1) Microcap Growth Fund, Inc. is affiliated with Commonwealth Associates, which has acted as underwriter and placement agent of the Company's securities for which it has received commissions and securities, and is a principal shareholder of the Company. (2) Warrants held of record by American Securities Corporation for benefit of BFG Bank Schweiz AG. (3) Northlea Partners Limited is an affiliate of John H. Abeles, a director of the Company. (4) Warrants held of record by American Securities Corporation for benefit of Maro Enterprises. -28- 29 (5) Dr. Soderquist was a director of the Company from December 1989 to October 27, 1994. (6) Joel S. Kanter was a director of the Company from June 1991 until April 21, 1995 and is President of Windy City, Inc. The Company has agreed to indemnify certain of the Selling Securityholders and these Selling Securityholders have agreed to indemnify the Company against certain civil liabilities, including liabilities under the Securities Act. Except as noted above, none of the Selling Securityholders has held any office or maintained any material relationship with the Company during the past three years. DESCRIPTION OF WARRANTS Each Warrant entitles the registered holder thereof to purchase one share of Common Stock at a price of $5.00, subject to adjustment in certain circumstances, at any time until October 14, 1997. The Warrants are redeemable by the Company until their expiration at any time commencing October 14, 1993, at a price of $.25 per warrant, provided that (i) notice of not less than 60 days is given to the warrantholders; (ii) the closing bid quotation of the Common Stock on all 20 of the trading days ending on the third day prior to the date on which the Company gives notice has been at least 150% (currently $7.50, subject to adjustment) of the then effective exercise price of the Warrants and (iii) the warrantholders shall have exercise rights until the close of business on the date fixed for redemption. The Warrants are issued in registered form under a Warrant Agreement between the Company and American Stock Transfer and Trust Company, as Warrant Agent. The exercise price and number of shares of Common Stock or other securities issuable on exercise of the Warrants are subject to adjustment in certain circumstances, including in the event of a stock dividend, stock split, recapitalization, reorganization, merger or consolidation of the Company. However, the Warrants are not subject to adjustment for issuances of Common Stock at a price below the exercise price of the Warrants, including the issuance of shares of Common Stock pursuant to the Company's employee benefit plans. Subject to compliance with the Securities Act as described below, the Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (by certified check payable to the Company) to the Warrant Agent for the number of Warrants being exercised. The warrantholders do not have the rights or privileges of holders of Common Stock. No Warrant will be exercisable unless at the time of exercise the Company has filed with the Commission a current prospectus covering shares of Common Stock issuable upon exercise of such warrant (and such shares have been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of such warrant). The Company will use its best efforts to maintain a current prospectus relating to the Warrants and all shares issuable on the exercise of the Warrants until the expiration of the Warrants, subject to the terms of the Warrant Agreement. While it is the Company's intention to do so, there is no assurance that it will be able to do so. No fractional shares will be issued upon exercise of the Warrants. However, if a warrantholder exercises all warrants then owned of record by it, the Company will pay to such warrantholder, in lieu of the issuance of any fractional share which is otherwise issuable, an amount in cash based on the market value of the Common Stock on the last trading day prior to the exercise date. PLAN OF DISTRIBUTION The Common Stock and Warrants offered hereby may be sold by the Selling Securityholders from time to time as market conditions permit in the over-the-counter market, or otherwise, at prices and terms then prevailing or at prices related to the then current market price, or in negotiated transactions. The shares offered hereby may be sold by one or more of the following methods, without limitation: (a) a block trade in which a broker or dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; (b) purchases by a broker or dealer as principal and resale by such broker or dealer for its account pursuant to this Prospectus; (c) ordinary brokerage transactions and transactions in which the broker solicits purchasers; and (d) face-to-face transactions between sellers and purchasers without a broker-dealer. In effecting sales, brokers or dealers engaged by the Selling Securityholders may arrange for other brokers or dealers to participate. Such brokers or dealers may receive commissions or discounts from Selling Securityholders in amounts to be negotiated immediately prior to the sale. Such brokers or dealers and any other participating brokers or dealers may be deemed to be "underwriters" within the meaning of the Securities Act of 1933, in connection with such sales. In addition, any securities covered by this Prospectus that qualify for sale pursuant to Rule 144 under the Securities Act might be sold under Rule 144 rather than pursuant to this Prospectus. LEGAL MATTERS The legality of the securities offered by this Prospectus will be passed upon for the Company by Graham & James LLP, Sacramento, California. Pursuant to an agreement between Graham & James LLP and the Company, on August 18, 1995 the Company (i) issued to Graham & James LLP 240,000 shares of Common Stock in lieu of cash payment of $150,000 in legal fees payable to Graham & James LLP and (ii) deposited into escrow $150,000 pursuant to an escrow agreement (the "Escrow Agreement") among Graham & James LLP, the Company and the escrow agent. None of the legal fees payable to Graham & James LLP were for legal services provided in connection with this Prospectus. Pursuant to the Escrow Agreement, funds were released to the Company in the amounts equal to the net proceeds realized by Graham & James LLP (if such proceeds were $0.625 per share or more). All funds in the escrow were released to the Company prior to the date of this Prospectus. The Company has registered the resale of such shares under the Securities Act on a registration statement pursuant to the Company's agreement with Graham & James LLP. Pursuant to an agreement between Graham & James LLP and the Company, the Company issued to Graham & James LLP on February 27, 1995 a warrant to purchase 140,000 shares of Common Stock at an exercise price of $0.25 per share at any time prior to February 2000. Such warrant was issued in lieu of cash payment of $105,000 in legal fees payable to Graham & James LLP for services unrelated to the preparation of this Prospectus. Certain partners of Graham & James LLP own an aggregate of 2,331 shares of Common Stock. EXPERTS -29- 30 The balance sheet of AccuMed, Inc as of December 31, 1994, and the statements of operations, shareholder's deficit, and cash flows for the period from February 7, 1994 (inception) through December 31, 1994, the balance sheets of Alamar Biosciences, Inc. as of September 30, 1995 and 1994, and the statements of operations, shareholder's equity, and cash flows for each of the three years in the period ended September 30, 1995, and the balance sheet of Sensititre/Alamar, the Microbiology Division of AccuMed, Inc., as of December 31, 1994 and the statements of net sales, cost of sales, and selling expenses for the eight months ended December 31, 1994 and for each of the two years in the period ended April 30, 1994, as incorporated by reference in the Post-effective Amendment No. 2 to the Registration Statement of which this Prospectus forms a part, have been incorporated herein in reliance on the reports, which included explanatory paragraphs related to AccuMed, Inc.'s and Alamar Biosciences, Inc.'s ability to continue as going concerns, of Coopers & Lybrand L.L.P., independent accountants, given on the authority of said firm as experts in accounting and auditing. The balance sheets of AccuMed International Limited as of December 31, 1994, April 30, 1994 and 1993, and the statements of operations and cash flows for the eight months ended December 31, 1994, and for each of the two years in the period ended April 30, 1994, as incorporated by reference in the Post-effective Amendment No. 2 to the Registration Statement of which this Prospectus forms a part, have been incorporated herein in reliance on the report of Coopers & Lybrand, independent accountants, given on the authority of said firm as experts in accounting and auditing. The consolidated financial statements of AccuMed International, Inc. and subsidiaries as of December 31, 1995, and for the three months ended December 31, 1995, incorporated by reference herein and elsewhere in the Registration Statement from the Company's Transition Report of Form 10-KSB for the transition period ended December 31, 1995, have been included therein and incorporated by reference herein and elsewhere in the Registration Statement in reliance upon the report of KPMG Peat Marwick LLP, independent certified public accountants, included therein and incorporated herein by reference, and upon the authority of said firm as experts in accounting and auditing. -30- 31 ================================================================================ No dealer, salesperson or any other person has been authorized to give any information or to make any representations other than those contained in this Prospectus and, if given or made, such information or representations must not be relied upon as having been authorized by the Company or any Selling Securityholder. This Prospectus does not constitute an offer to sell or the solicitation of any offer to buy any security other than the shares of Common Stock offered by this Prospectus, nor does it constitute an offer to sell or a solicitation of any offer to buy the shares of Common Stock by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which the person making such offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation. Neither the delivery of this Prospectus nor any sale made hereunder shall, under any circumstances, create any implication that information contained herein is correct as of any time subsequent to the date hereof. ================================================================================ ================================================================================ 2,069,028 Shares 574,905 Warrants ACCUMED INTERNATIONAL, INC. Common Stock and Redeemable Warrants to Purchase Common Stock ______________ PROSPECTUS ______________ ================================================================================ 32 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by the Company in connection with the issuance and distribution of the securities being registered hereunder. All of the amounts shown are estimates (except for the SEC registration fee). SEC registration fee.................................. $ 3,860 Printing and engraving expenses........................ 7,000 Accounting fees and expenses........................... 2,000 Legal fees and expenses............................... 31,000 Blue Sky fees and expenses............................ 14,000 Miscellaneous......................................... 2,140 ------ TOTAL................................................ $60,000
None of these expenses will be paid by the Selling Securityholders pursuant to the terms of the agreements under which the shares of Common Stock and Warrants to be sold hereby were issued. Item 15. Indemnification of Directors and Officers The Company has provisions in its Certificate of Incorporation which eliminate the liability of the Company's directors to the Company and its shareholders for monetary damages to the fullest extent permissible under Delaware law and provisions which authorize the Company to indemnify its directors and agents by bylaws, agreements or otherwise, to the fullest extent permitted by law. Such limitation of liability does not affect the availability of equitable remedies such as injunctive relief or rescission. The Company's Bylaws provide that the Company shall indemnify its directors and officers to the fullest extent permitted by Delaware law. The Company's officers and directors are covered by a director's and officer's liability insurance policy maintained by the Company. Under the insurance policy, the Company is entitled to be reimbursed for indemnity payments that it is required or permitted to make to its directors and officers. Item 16. Exhibits Exhibit Number ------ 4.1 Certificate of Incorporation of the Registrant (incorporated by reference to the II-2 33 Registrant's Transition Report of Form 10-KSB for the transition period ended December 31, 1995 (the "Transition Report)). 4.2 Specimen Certificate for Common Stock (incorporated by reference to the Transition Report). 4.3 Bylaws of the Registrant (incorporated by reference to Transition Report). 4.4 Warrant Agent Agreement (incorporated by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-KSB for the fiscal year ended September 30, 1992 (the "1992 10-K"). 4.5 Specimen Certificate for Warrant (incorporated by reference to Pre-Effective Amendment No. 4 to Form S-1 (Regis. No. 33-48302), filed with the Commission on October 9, 1993 ("Pre-Effective Amendment No. 4")). 4.6 Certificate of Appointment of American Stock Transfer & Trust Company as Transfer Agent and Registrar (incorporated by reference to Exhibit 4.4 to Pre-Effective Amendment No. 4) 4.7 Form of Securities Purchase Agreement with respect to the Conversion of Warrants by U.S. Persons entered into between the Company and the certain Selling Securityholders (previously filed as Exhibit 4.5 to this Registration Statement on Form SB-2 on September 16, 1993 (the "Form SB-2"). 4.8 Form of Securities Purchase Agreement with respect to the Conversion of Warrants by non-U.S. Persons entered into between the Company and certain Selling Securityholders (previously filed with this Registration Statement on September 13, 1993). 4.9 Form of Securities Purchase Agreement with respect to the Regulation S offering of securities to non-U.S. persons entered into between the Company and certain Selling Securityholders (previously filed with this Registration Statement on September 13, 1993). 4.10 Securities Purchase Agreement, dated July 30, 1993, between the Company and Commonwealth Associates Growth Fund, Inc. (renamed Microcap Growth Fund, Inc.) (previously filed with this Registration Statement on September 13, 1993). 4.11 Securities Registration Agreement, dated July 30, 1993, between the Company and Commonwealth Associates Growth Fund, Inc. (renamed Microcap Growth Fund, Inc.) (previously file with this Registration Statement on September 13, 1993). 5.1 Opinion of Graham & James, Counsel to the Registrant (previously filed with this Registration Statement on September 13, 1993). 23.1 Consent of Graham & James (contained in Exhibit 5.1) II-3 34 23.2 Consent of Coopers & Lybrand LLP 23.3 Consent of Coopers & Lybrand (U.K.) 23.4 Consent of KPMG Peat Marwick LLP 24.1 Powers of Attorney (included on signature page hereto) Item 17. Undertakings (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to include any additional or changed material information with respect to the plan of distribution. (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the Act") may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. (b) The Registrant hereby deregisters the following securities previously included on this Registration Statement: (1) 250,000 shares of Common Stock previously held by Commonwealth Growth Fund, Inc. (renamed Microcap Growth Fund, Inc.). (2) 220,119 shares of Common Stock issuable upon exercise of a warrant issued to Commonwealth Associates which has been cancelled (the "Cancelled Warrant"). (3) 220,119 shares of Common Stock underlying warrants underlying the Cancelled Warrant. II-4 35 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 2 on Form S-3 to the Registration Statement of Form SB-2 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, State of Illinois on May 24, 1996. ACCUMED INTERNATIONAL, INC. By: \s\ PETER P. GOMBRICH ------------------------- Peter P. Gombrich, Chief Executive Officer POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each of the persons whose signatures appear below constitute and appoint, jointly and severally, Peter P. Gombrich and Mark L. Santor, and each of them, attorneys-in-fact for the undersigned, each with the power of substitution, for the undersigned in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming that each of said attorneys-in-fact or his substitute or substitutes may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 on Form S-3 to the Registration Statement on Form SB-2 has been signed by the following persons in the capacities and on the dates indicated. Signature Title Date --------- ----- ---- \s\ PETER P. GOMBRICH Chairman of the Board and May 24, 1996 --------------------- Chief Executive Officer (Peter P. Gombrich) (Principal Executive Officer) \s\ MARK L. SANTOR Vice President, Finance and May 24, 1996 --------------------- Chief Financial Officer (Mark L. Santor) (Principal Financial and Accounting Officer) Director , 1996 --------------------- ------------- (John H. Abeles) \s\ RICHARD D. CORBIN Director May 24, 1996 --------------------- (Richard Corbin) \s\ JACK HALPERIN Director May 24, 1996 --------------------- (Jack Halperin) \s\ PAUL F. LAVALLE Director May 24, 1996 --------------------- (Paul F. Lavalle) II-5 36 \s\ JOSEPH PLANDOWSKI Director May 24, 1996 --------------------- (Joseph Plandowski) \s\ LEONARD SCHILLER Director May 24, 1996 --------------------- (Leonard Schiller) II-6 EX-23.2 2 CONSENT OF INDEPENDENT ACCOUNTANTS 1 EXHIBIT 23.2 CONSENT OF INDEPENDENT ACCOUNTANTS We consent to the incorporation by reference in this post-effective amendment No. 2 to Form SB-2 (SEC File No. 33-68932) of our report, which includes an explanatory paragraph related to substantial doubt about the ability of AccuMed, Inc. to continue as a going concern, dated September 29, 1995, on our audit of the balance sheet of AccuMed, Inc. as of December 31, 1994, and for the period from February 7, 1994 (inception) through December 31, 1994, appearing in the registration statement on form S-4 (SEC File No. 33-99680) of Alamar Biosciences, Inc. filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933 as incorporated by reference in the Current Report on Form 8-K dated December 29, 1995. We also consent to the reference to our firm under the caption "Experts." /S/Coopers & Lybrand L.L.P. Sacramento, CA May 24, 1996 2 EXHIBIT 23.2 continued CONSENT OF INDEPENDENT ACCOUNTANTS We consent to the incorporation by reference in this post-effective amendment No. 2 to Form SB-2 (SEC File No. 33-68932) of our report , which includes an explanatory paragraph related to substantial doubt about the ability of Alamar Biosciences, Inc. to continue as a going concern, dated November 19, 1995, on our audits of the financial statements of Alamar Biosciences, Inc. as of September 30, 1995 and 1994, and for the years ended September 30, 1995, 1994 and 1993, which report is included in the Annual Report on Form 10-KSB for the year ended September 30, 1995. We also consent to the reference to our firm under the caption "Experts." /S/Coopers & Lybrand L.L.P. Sacramento, CA May 24, 1996 3 EXHIBIT 23.2 continued CONSENT OF INDEPENDENT ACCOUNTANTS We consent to the incorporation by reference in this post-effective amendment No. 2 to Form SB-2 (SEC File No. 33-68932) of our report dated September 14, 1995, on our audit of the balance sheet of Sensititre/Alamar, the Microbiology Division of AccuMed, Inc., as of December 31,1994, and the net sales, cost of sales and selling expenses for the eight months ended December 31, 1994, and the years ended April 30, 1994 and 1993, appearing in the registration statement on form S-4 (SEC File No. 33-99680) of Alamar Biosciences, Inc. filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933 as incorporated by reference in the Current Report on Form 8-K dated December 29, 1995. We also consent to the reference to our firm under the "Experts." /S/Coopers & Lybrand L.L.P. Sacramento, CA May 24, 1996 EX-23.3 3 CONSENT OF INDEPENDENT ACCOUNTANTS 1 EXHIBIT 23.3 CONSENT OF INDEPENDENT ACCOUNTANTS We consent to the incorporation by reference in this post-effective amendment No. 2 to Form SB-2 (SEC File No. 33-68932) of our report dated December 8, 1995, on our audit of the balance sheets of AccuMed International Limited as of December 31 1994, April 30, 1994 and 1993, and related statements of operations and cashflows for the eight months ended December 31, 1994, and the years ended April 30, 1994 and 1993, appearing in the registration statement on Form S-4 (SEC File No. 33-99680) of Alamar Biosciences, Inc. filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933 as incorporated by reference in the current Report on Form 8-K dated December 29, 1995. /S/Coopers & Lybrand Croydon United Kingdom May 24, 1996 EX-23.4 4 CONSENT OF INDEPENDENT AUDITORS 1 EXHIBIT 23.4 INDEPENDENT AUDITORS' CONSENT The Board of Directors Accumed International, Inc. We consent to incorporation by reference in the registration statement (No. 33-68932) on Form S-3 of AccuMed International, Inc. of our report dated April 5, 1996, relating to the consolidated balance sheet of AccuMed International, Inc., and subsidiaries as of December 31, 1995 and the related consolidated statements of operations, stockholders' equity and cash flows for the three months ended December 31, 1995, which report appears in the December 31, 1995 transition report on form 10-KSB of AccuMed International, Inc. We also consent to the reference to our firm under the caption "Experts." KPMG Peat Marwick LLP Chicago, Illinois May 24, 1996 -----END PRIVACY-ENHANCED MESSAGE-----